BiotechTube

ASP8731 + ASP8731 Matching Placebo

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Participants

Conditions

Healthy Participants

Trial Timeline

Mar 7, 2022 → Nov 10, 2022

NCT ID
NCT05167526

About ASP8731 + ASP8731 Matching Placebo

ASP8731 + ASP8731 Matching Placebo is a phase 1 stage product being developed by Astellas Pharma for Healthy Participants. The current trial status is terminated. This product is registered under clinical trial identifier NCT05167526. Target conditions include Healthy Participants.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05167526Phase 1Terminated

Competing Products

20 competing products in Healthy Participants

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
33
ValsartanNovartisPhase 1
33
CSL112 + PlaceboCSLPhase 1
32
UT-15CUnited TherapeuticsPhase 1
30
VNA-318 + PlaceboBiotrialPhase 1
25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
25
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
25
Radiolabeled TRV130TrevenaPhase 1
25
TRV130A + Dextrose in WaterTrevenaPhase 1
25
TRV734TrevenaPhase 1
25
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
33
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
33
KPL-404Kiniksa PharmaceuticalsPhase 1
28
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
33
Propranolol + PseudoephedrineEli LillyPre-clinical
23
LY2157299Eli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 1
33
LY3015014 + PlaceboEli LillyPhase 1
33
LOXO-783Eli LillyPhase 1
33
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85